撰文丨王聪 编辑丨王多鱼 排版丨水成文 多囊卵巢综合征 （PCOS） 是育龄女性中最常见的内分泌紊乱疾病，具有高度遗传性，但我们对其多基因结构仍知之甚少。 2025 年 11 月 4 日，中国科学院脑科学与智能技术卓越创新中心 师咏勇 团队联合山东大学/ 生殖医学与子代健康全国重点实验室 赵涵 教授、 青岛大学/青岛大 学附属医院 李志强 教授、安徽医科大学 曹云霞 教授等，在 Nature Genetics 期刊发表了题为： Multi-ancestry genome-wide association analyses of polycystic ovary syndrome 的研究论文。 在这项最新研究中，研究团队对 12419 名中国 多囊卵巢综合征 （PCOS） 患者和 34235 名对照者进行了全基因组关联研究 （GWAS） ，随后与多达 13773 名欧洲病例和 411088 名对照者进行了多祖先荟萃分析，进而确定了 94 个独立遗传位点，其中 73 个此前未被报道。 该研究发现，尽管进化压力不同，但中国和欧洲血统显示出大量的遗传重叠。功能注释发现， AMH 基因上的错义突变 rs10407022 ...

Group 1 - Tianyu Co., Ltd. (SZ300702) has received preliminary approval for an environmental impact assessment for its subsidiary Binhai Sannong Pharmaceutical Chemical Co., Ltd.'s expansion and technical renovation project, which includes the production of various pharmaceutical products with a total investment of 85.55 million yuan [1] - The "A-share Green Report" project aims to enhance transparency in environmental information of listed companies, utilizing authoritative environmental regulatory data from 31 provinces and 337 cities [1] - The latest A-share Green Weekly Report indicated that four listed companies recently exposed environmental risks [1] Group 2 - Tianyu Co., Ltd.'s main business segments include generic drug raw materials and intermediates (72.18% of revenue), CDMO raw materials and intermediates (16.02%), formulations (11.43%), and others (0.37%) as of the 2025 semi-annual report [3] - The company's market capitalization is approximately 9.472 billion yuan, with reported revenues of 2.527 billion yuan for 2023, 2.631 billion yuan for 2024, and 1.567 billion yuan for the first half of 2025 [4] - The net profit attributable to the parent company is projected to be 273.593 million yuan for 2023, 559.351 million yuan for 2024, and 1.495118 billion yuan for the first half of 2025 [4]

Group 1 - The core point of the article is that Tianyu Co., Ltd. has received the CEP certificate from the European Medicines Agency for the active pharmaceutical ingredient of Telmisartan, which is used for treating primary hypertension and reducing cardiovascular risk [1] Group 2 - The announcement highlights the significance of the CEP certificate in ensuring the quality and compliance of the pharmaceutical product in the European market [1] - Telmisartan is specifically indicated for the treatment of primary hypertension and plays a role in lowering cardiovascular risk, indicating its importance in the healthcare sector [1]

Core Insights - The report maintains a positive outlook on the pharmaceutical and biotechnology sector, with a focus on raw material prices as of July 2025 [1][3] Hormonal Drug Price Situation - In July 2025, prices for hormonal drugs such as progesterone, medroxyprogesterone acetate, saponin, dexamethasone sodium phosphate, hydrocortisone, and acetate hydrocortisone remained stable month-on-month. Year-on-year, progesterone prices remained unchanged, while medroxyprogesterone acetate, saponin, dexamethasone sodium phosphate, hydrocortisone, acetate hydrocortisone, and saponin saw declines of 1.85%, 3.23%, 84.22%, 14.04%, 12.15%, and 5.66% respectively [6][10] Antibiotic Intermediate Price Situation - In July 2025, prices for antibiotic intermediates such as 4-AA remained stable month-on-month, while 7-ADCA, 7-ACA, 6-APA, and penicillin industrial salt saw decreases of 1.92%, 2.08%, 8.33%, and 7.89% respectively. Year-on-year, 7-ADCA, 7-ACA, 6-APA, 4-AA, and penicillin industrial salt prices fell by 1.92%, 4.08%, 45.00%, 13.92%, and 41.67% respectively [10][11] β-Lactam Antibiotic Price Situation - In July 2025, prices for β-lactam antibiotics such as cephalexin, ampicillin, cefotaxime sodium, and cefaclor remained stable month-on-month. However, ceftriaxone sodium, cefixime, and amoxicillin saw declines of 1.55%, 1.37%, and 11.36% respectively. Year-on-year, cephalexin, ampicillin, ceftriaxone sodium, cefotaxime sodium, cefixime, and amoxicillin prices decreased by 1.82%, 2.22%, 9.29%, 3.40%, 12.20%, and 35.00% respectively, while cefaclor saw an increase of 6.12% [15][17] Cardiovascular Drug Price Situation - In July 2025, prices for cardiovascular raw materials such as valsartan, irbesartan, telmisartan, lisinopril, enalapril maleate, and atorvastatin calcium remained stable month-on-month. Year-on-year, valsartan prices decreased by 1.54%, while the other drugs remained unchanged [19][20]

Core Viewpoint - The company has successfully obtained GMP certification from Brazil's National Health Surveillance Agency (ANVISA) for four chemical raw materials, indicating compliance with international quality standards [1] Group 1: Certification Details - The GMP certification was conducted from March 17 to March 21, 2025, covering the following products: Candesartan Cilexetil, Sacubitril/Valsartan, Telmisartan, and Valsartan [1] - The certification is valid until May 26, 2027, and June 9, 2027, respectively, for the two certificates issued by ANVISA [1] - The on-site inspection by ANVISA concluded that the company’s facilities met the required standards, resulting in a qualified status for the four raw material products [1]